NCT02696096

Brief Summary

This study proposes to use functional magnetic resonance imaging (FMRI) to observe brain activity and behavior associated with decision-making about rewards (DD task), working memory and working memory cognitive persistence (WM task), and craving (CR task) in 72 opiate dependent participants initiating buprenorphine. While stably using opiates (initial study appointment) and again during withdrawal (approximately 3 days later), participants will receive an FMRI scan with behavioral challenges; immediately after the second FMRI, they will receive their first dose of buprenorphine. Buprenorphine treatment will continue for twelve weeks, followed by a four week taper. Urine toxicological analysis will be performed prior to the first scanning session, weekly for two weeks and biweekly thereafter. Participation for all individuals will last 4 months. Assessments will occur at baseline, and weeks 1, 2, 4, 8, and 12. Buprenorphine induction will begin at the completion of the second scan; follow-up medical visits will align with study assessments on weeks 1, 2, 4, 8 and 12. All participants will receive 16 weeks of buprenorphine (the final 4 of these 16 weeks will include a taper).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
21

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Aug 2016

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 9, 2016

Completed
22 days until next milestone

First Posted

Study publicly available on registry

March 2, 2016

Completed
5 months until next milestone

Study Start

First participant enrolled

August 1, 2016

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2020

Completed
2.5 years until next milestone

Results Posted

Study results publicly available

August 17, 2022

Completed
Last Updated

August 17, 2022

Status Verified

July 1, 2022

Enrollment Period

3.5 years

First QC Date

February 9, 2016

Results QC Date

November 30, 2021

Last Update Submit

July 19, 2022

Conditions

Outcome Measures

Primary Outcomes (3)

  • Changes in Resting State Disorganization Between Baseline and One Week by Person by Lapsed Category

    The measure of resting state organization is a z-value derived from Pearson's r-values. They represent the effect of the association between the brain activity of the seed region and each brain voxel over time during the resting state FMRI scan. A central z-value of 0 means that there is no association between the seed region and the voxel. Positive and negative z-values approaching 0 reflect increasingly weaker associations, and more extreme positive and negative values reflect stronger associations. Attributing the qualitative labels better or worse to these values depend upon the brain network and context. In many networks (eg, task-positive cognitive control network), a stronger positive correlation is thought to reflect better network organization. In the task-negative default mode network a stronger positive relationship is considered by some as worse. For this study, these are not yet used as clinical measures and there are not known cutoffs.

    Baseline and 1 week

  • Working Memory - Between Groups at Baseline by Lapsed Category

    fMRI working memory differences between participants who lapse back to opioid use and those who don't

    Baseline

  • Changes in Working Memory - Within Groups During Satiation and Withdrawal

    fMRI working memory differences under satiation vs withdrawal from opioids

    Baseline and 1 week

Study Arms (1)

All Participants

OTHER

FMRI Suboxone

Other: FMRIDrug: Suboxone

Interventions

FMRIOTHER

all participants will complete 2 FMRIs

Also known as: functional magnetic resonance imaging
All Participants

all participants will be prescribed Suboxone for 4 months during their study participation

Also known as: buprenorphine
All Participants

Eligibility Criteria

Age21 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • opiate dependent persons
  • years old
  • interested in initiating outpatient buprenorphine treatment

You may not qualify if:

  • current methadone maintenance treatment program participation
  • medically necessary prescription opiate treatment (e.g., for chronic pain)
  • current criteria for a DSM-V diagnosis of substance dependence for sedative or hypnotic drugs, alcohol, stimulants, cocaine, inhalants, hallucinogens
  • diagnosis of organic brain disorder, bipolar disorder, schizophrenia, schizo-affective, schizophreniform or paranoid disorder
  • current suicidality on the Modified Scale for Suicidal Ideation
  • evidence of neuropsychological dysfunction as assessed by the study physician with confirmation with the Folstein Mini-Mental Status Examination•
  • anticipated major painful event (significant surgical procedure) in the coming 4 months
  • probation or parole requirements or an upcoming move that might interfere with protocol participation
  • history of allergic reaction to buprenorphine or naloxone
  • currently pregnant or planning to become pregnant in the next 4 months
  • history of neurological disorder (e.g., epilepsy, stroke, brain injury)
  • impaired uncorrected vision
  • FMRI contraindications (e.g., claustrophobia, specific metallic implants and injuries)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Butler Hospital

Providence, Rhode Island, 02906, United States

Location

MeSH Terms

Conditions

Opioid-Related Disorders

Interventions

Buprenorphine, Naloxone Drug CombinationBuprenorphine

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

MorphinansOpiate AlkaloidsAlkaloidsHeterocyclic CompoundsNaloxoneHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsDrug CombinationsPharmaceutical Preparations

Results Point of Contact

Title
Dr. Michael Stein
Organization
Butler Hospital

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle Investigator

Study Record Dates

First Submitted

February 9, 2016

First Posted

March 2, 2016

Study Start

August 1, 2016

Primary Completion

February 1, 2020

Study Completion

February 1, 2020

Last Updated

August 17, 2022

Results First Posted

August 17, 2022

Record last verified: 2022-07

Locations